Shield's Accrufer MA application accepted in China
3rd Mar 2026 13:32
(Sharecast News) - Shield Therapeutics said the Chinese National Medical Products Administration has accepted a marketing authorisation application for Accrufer, or ferric maltol, for the treatment of iron deficiency in adults.
Read moreShield Therapeutics reports strongest quarterly performance to date
23rd Oct 2025 11:56
(Sharecast News) - Shield Therapeutics reported its strongest quarterly performance to date on Thursday, with third-quarter Accrufer prescriptions rising about 15% from the previous quarter and revenues reaching a new high, keeping the company on track to become cash flow positive by year-end.
Read moreShield Therapeutics gets FDA priority review to extend Accrufer indication
4th Sep 2025 13:24
(Sharecast News) - Shield Therapeutics said on Thursday that the US Food and Drug Administration (FDA) has granted priority review to extend the indication of its oral iron therapy Accrufer/Feraccru to adolescents aged 10 and above, with potential approval expected in 2026.
Read moreShield Therapeutics reports sharp rise in first-half revenue
3rd Sep 2025 13:06
(Sharecast News) - Shield Therapeutics reported a sharp rise in first-half revenue on Wednesday, as sales of its oral iron therapy Accrufer accelerated across key markets, leaving the company on track to reach cash flow breakeven by the end of 2025.
Read moreShield Therapeutics inks exclusive licence agreement in Japan
22nd Apr 2025 09:03
(Sharecast News) - Pharmacitucal firm Shield Therapeutics said on Tuesday that it had inked an exclusive licence agreement for its ACCRUFeR iron deficiency asset in Japan with VITAL-NET.
Read moreShield Therapeutics appoints Anders Lundstrom as permanent CEO
27th Jan 2025 15:40
(Sharecast News) - Shield Therapeutics announced the appointment of Anders Lundstrom as its permanent chief executive officer on Monday, effective 1 February.
Read moreShield Therapeutics secures $10m investment, announces RetailBook offer
6th Dec 2024 11:46
(Sharecast News) - Shield Therapeutics announced on Friday that it has secured a $10m investment from its largest shareholder, AOP Health International Management, through a subscription of 256.4 million new shares at 3p per share.
Read moreShield Therapeutics reports strong quarter for Accrufer
29th Oct 2024 09:46
(Sharecast News) - Shield Therapeutics reported a strong third-quarter performance for its iron deficiency treatment Accrufer in the US on Tuesday, achieving net revenue of $7.2m.
Read moreShield Therapeutics announces promising paediatric trial results
25th Sep 2024 14:56
(Sharecast News) - Shield Therapeutics announced promising results from its phase three paediatric clinical trial for 'Accrufer' and 'Ferracru', or ferric maltol, in treating iron deficiency anaemia (IDA) in children on Wednesday.
Read moreShield Therapeutics iron deficiency treatment approved in Canada
27th Aug 2024 12:28
(Sharecast News) - Commercial-stage pharmaceutical company Shield Therapeutics announced on Tuesday that 'ACCRUFeR', or ferric maltol, had been approved by Health Canada as a prescription drug for the treatment of adults with iron deficiency anaemia (IDA).
Read moreShield Therapeutics net sales grow in Q2, CEO stands down
24th Jul 2024 09:15
(Sharecast News) - Commercial-stage pharmaceutical company Shield Therapeutics said on Wednesday that total net sales had grown in Q2, driven by "robust" increases in prescriptions and higher net selling prices.
Read moreShield Therapeutics reports strong US progress
7th Dec 2023 13:11
(Sharecast News) - Iron deficiency-focussed pharmaceuticals company Shield Therapeutics announced significant achievements in the US commercialisation of Accrufer on Thursday.
Read moreShield's Canadian partner files new drug submission for Accrufer
21st Mar 2022 11:58
(Sharecast News) - Commercial-stage pharmaceutical company Shield Therapeutics announced on Monday that KYE Pharmaceuticals has submitted a new drug submission to Health Canada, for the regulatory review and approval of the iron therapy 'Accrufer'.
Read moreShield Therapeutics revenue falls in line with expectations
17th Feb 2022 15:51
(Sharecast News) - Commercial-stage pharmaceutical company Shield Therapeutics reported total 2021 revenue of £1.5m in a trading update on Thursday, in line with market expectations.
Read moreShield Therapeutics enters Accrufer licensing deal in Canada
5th Jan 2022 13:43
(Sharecast News) - Commercial-stage pharmaceutical company Shield Therapeutics has entered into an exclusive licence agreement for 'Accrufer', it announced on Wednesday, with KYE Pharmaceuticals in Canada.
Read more